Population pharmacokinetic modeling of benznidazole in Brazilian patients with chronic Chagas disease

Rev Inst Med Trop Sao Paulo. 2022 Feb 2:64:e4. doi: 10.1590/S1678-9946202264004. eCollection 2022.

Abstract

The present study aimed to establish a population pharmacokinetic (PopPK) modeling of benznidazole (BZD) in Brazilian patients with chronic Chagas disease. This was part of a Brazilian prospective cohort study with eight patients diagnosed with Chagas disease during the beginning of BZD treatment up to the 60th day. On the 15th day of treatment, a blood sampling was collected and analyzed. A one-compartment PK model was developed using Pmetrics. Patients with an average age of 50.3 (SD: 6.2) years old, 6 female patients and 2 males, 70.2 kg (14.2), receiving a 5 mg/Kg/day dose were included. PK parameters estimated for CL, V and Ka were 6.27 L/h, 38.97 L and 1.66 h-1, respectively. This is the first study to establish a population pharmacokinetic modeling of BZD in Brazilian patients with chronic Chagas disease. Therefore, further studies are needed to obtain the complete characterization of BZD pharmacokinetics.

MeSH terms

  • Chagas Disease* / drug therapy
  • Child
  • Female
  • Humans
  • Male
  • Middle Aged
  • Nitroimidazoles* / therapeutic use
  • Prospective Studies
  • Trypanocidal Agents* / therapeutic use

Substances

  • Nitroimidazoles
  • Trypanocidal Agents
  • benzonidazole